Additionally, we categorized the patients via the molecular subtyping of common mutations such as NPM1 and FLT3, as well as the recurrent fusions, including AML-1::ETO, CBFB::MYH11, PML::RARA, etc. We correlated the m6A-associated gene expression with different molecular subtypes and evaluated their prognostic and clinical implications. This evidence concerns the gene NPM1 and acute myeloid leukemia.